Soleus Capital Management L.P. Invests $19.82 Million in Ascendis Pharma A/S (NASDAQ:ASND)

Soleus Capital Management L.P. bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 144,000 shares of the biotechnology company's stock, valued at approximately $19,824,000. Ascendis Pharma A/S comprises about 1.2% of Soleus Capital Management L.P.'s holdings, making the stock its 24th largest position. Soleus Capital Management L.P. owned approximately 0.24% of Ascendis Pharma A/S as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Rice Hall James & Associates LLC lifted its holdings in Ascendis Pharma A/S by 2.0% in the fourth quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company's stock valued at $22,562,000 after acquiring an additional 3,274 shares during the period. abrdn plc lifted its holdings in Ascendis Pharma A/S by 18.3% in the fourth quarter. abrdn plc now owns 187,180 shares of the biotechnology company's stock valued at $25,769,000 after acquiring an additional 28,967 shares during the period. Blue Trust Inc. lifted its holdings in Ascendis Pharma A/S by 540.5% in the fourth quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company's stock valued at $76,000 after acquiring an additional 427 shares during the period. New York State Common Retirement Fund lifted its holdings in Ascendis Pharma A/S by 14.0% in the fourth quarter. New York State Common Retirement Fund now owns 204,482 shares of the biotechnology company's stock valued at $28,151,000 after acquiring an additional 25,164 shares during the period. Finally, Proficio Capital Partners LLC acquired a new position in Ascendis Pharma A/S in the fourth quarter valued at approximately $1,725,000.

Ascendis Pharma A/S Trading Up 1.2%

NASDAQ:ASND traded up $1.95 during trading hours on Friday, hitting $162.00. The company had a trading volume of 212,034 shares, compared to its average volume of 486,735. The company has a 50-day moving average of $157.41 and a 200 day moving average of $143.59. The company has a market cap of $9.88 billion, a P/E ratio of -22.82 and a beta of 0.41. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The business had revenue of $123.97 million during the quarter, compared to the consensus estimate of $98.56 million. On average, analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ASND shares. Evercore ISI upped their target price on Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $200.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, May 12th. Royal Bank of Canada upped their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. The Goldman Sachs Group upped their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Finally, JPMorgan Chase & Co. upped their target price on Ascendis Pharma A/S from $200.00 to $245.00 and gave the stock an "overweight" rating in a research note on Friday, May 2nd. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat.com, Ascendis Pharma A/S presently has a consensus rating of "Moderate Buy" and an average price target of $216.07.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.